Monotherapy: Fortesia Tablet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus.
Combination with metformin: Fortesia is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin as initial therapy or when the single agent alone, with diet and exercise does not provide adequate glycaemic control. Initial combination therapy or maintenance of combination therapy may not be appropriate for all patients. These management options are left to the discretion of the health care provider.
Combination with a sulphonylurea: Fortesia is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with sulphonylurea when treatment with maximal tolerated dose of sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.
Combination with metformin and sulphonylurea: Fortesia is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and a sulphonylurea when dual therapy with these two agents and with diet and exercise does not provide adequate glycaemic control.
Combination with peroxisome proliferator-activated receptor gamma (PPARy) agonist: Fortesia is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with a PPARy agonist (i.e., thiazolidinediones) when diet and exercise, plus the single agent do not provide adequate glycaemic control.
Combination with metformin and a PPARy agonist: Fortesia is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with metformin and PPARy agonist (i.e thiazolidinediones) when dual therapy with these agents, with diet and exercise does not provide adequate control.
Combination with insulin: Fortesia is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in combination with insulin (with or without metformin).